- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Visão geral do estudo
Status
Condições
Descrição detalhada
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Número de telefone: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
Estude backup de contato
- Nome: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Número de telefone: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
Locais de estudo
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, Índia, 522503
- Recrutamento
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Contato:
- Dr S Sathiyanarayanan, MBBS., MD
- Número de telefone: 08645 280021
- E-mail: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, Índia, 781101
- Ativo, não recrutando
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, Índia, 360001
- Ainda não está recrutando
- Govt. PDU Medical College
-
Contato:
- Dr Bhoomika Patel, MBBS., MD
- Número de telefone: 0281 245 8337
- E-mail: doctorbhoomika@gmail.com
-
Surat, Gujarat, Índia, 395001
- Ativo, não recrutando
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, Índia, 400008
- Recrutamento
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Contato:
- Dr Priti Meshram, MBBS., MD., DNB
- Número de telefone: 022 2373 5555
- E-mail: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, Índia
- Ainda não está recrutando
- All India Institute Of Medical Sciences, Nagpur
-
Contato:
- Dr Yogesh Bahurupi, MBBS., MD
- Número de telefone: 0712 2352078
- E-mail: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, Índia, 793018
- Recrutamento
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Contato:
- Dr Monaliza Lyngdoh, MBBS., MD
- Número de telefone: 0364 2538013
- E-mail: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Índia, 110030
- Ainda não está recrutando
- National Institute of TB and Respiratory Diseases
-
Contato:
- Dr Jitendra Kumar Saini, MBBS., MD
- Número de telefone: 011 2651 3325
- E-mail: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, Índia, 751019
- Ativo, não recrutando
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, Índia, 751001
- Ativo, não recrutando
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Índia, 600031
- Recrutamento
- ICMR - National Institute for Research in Tuberculosis
-
Contato:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Número de telefone: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
-
Contato:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Número de telefone: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
-
Investigador principal:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Investigador principal:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Subinvestigador:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, Índia, 500038
- Recrutamento
- Govt. General and Chest Hospital, Osmania Medical College
-
Contato:
- Dr V Karthik, MBBS., MD
- Número de telefone: 04083814421
- E-mail: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, Índia, 282002
- Recrutamento
- Sarojini Naidu Medical College
-
Contato:
- Dr Gajendra Vikram Singh, MBBS., MD
- Número de telefone: 0562 2260353
- E-mail: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, Índia, 211002
- Recrutamento
- Moti Lal Nehru Medical College
-
Contato:
- Dr Amitabh Das Shukla, MBBS., MD
- Número de telefone: 0532 261 3592
- E-mail: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, Índia, 226003
- Recrutamento
- King George Medical University
-
Contato:
- Dr Rajiv Garg, MBBS., MD
- Número de telefone: 0522 2255167
- E-mail: rajivkgmc@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimental: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Comparador Ativo: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Prazo: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Prazo: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Prazo: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Prazo: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Prazo: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Prazo: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Investigador principal: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publicações e links úteis
Publicações Gerais
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções do Trato Respiratório
- Infecções
- Doenças Respiratórias
- Doenças pulmonares
- Infecções por Bactérias Gram-Positivas
- Infecções bacterianas
- Infecções Bacterianas e Micoses
- Infecções por Actinomycetales
- Infecções por Mycobacterium
- Tuberculose
- Tuberculose Pulmonar
- Qualidade, acesso e avaliação da assistência médica
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Terapêutica
- Mecanismos de avaliação de saúde
- Qualidade de assistência médica
- Compostos policíclicos
- Compostos heterocíclicos, 4 ou mais anéis
- Rifamicinas
- Lactamas, macrocíclicas
- Compostos macrocíclicos
- Fluoroquinolonas
- 4-quinolonas
- Quinolones
- Quinolinas
- Ofloxacina
- Características do estudo epidemiológico
- Rifampicina
- Levofloxacina
- Protocolos clínicos
Outros números de identificação do estudo
- 2025 011
- CTRI/2026/02/102698 (Identificador de registro: CLINICAL TRIALS REGISTRY - INDIA)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .